RxDoctor Payments Data

Enrique Peralta

Ophthalmology · Saint Louis, MONPI 1346237534

Payments from drug & device makers

$3,881in general payments, 2019–2025

Across 121 payments — averaging $32.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$906
  • AbbVie$547
  • Alimera Sciences, Inc.$544
  • Regeneron Healthcare Solutions, Inc.$482
  • Astellas Pharma US Inc$464
  • Apellis Pharmaceuticals, Inc.$221
  • plus $718 from 11 others

What the payments were for

  • Food & beverage$3,78798%
  • Education$942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,881 in reported general payments places this provider in the 65th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$1,193,086
Medicare patients
456
Services billed
16,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate149$5,681
LumiganBimatoprost11$4,599
Ketorolac Tromethamine149$3,266
Tobramycin-DexamethasoneTobramycin/Dexamethasone54$2,257
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,089
Brimonidine Tartrate43$1,038
Latanoprost94$664
Timolol Maleate64$500
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$367
Dorzolamide Hcl13$292
Ciprofloxacin Hcl18$201
Acetaminophen-CodeineAcetaminophen With Codeine30$107
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha12$77
Prednisone11$51
Ibuprofen19$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$547$4,59911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →